Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, pharmacokinetics, and anti-tumor activity of MK-8808 in
combination with cyclophosphamide, vincristine, and prednisolone (CVP), and as a single
agent, for participants with B-lymphocyte antigen cluster of differentiation 20
(CD20)-positive follicular lymphoma who have had no prior chemotherapy. The primary study
hypothesis is that MK-8808 will be safe and well tolerated in combination with CVP and as a
single agent.